+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Axial Spondyloarthritis - Pipeline Review, H2 2019

  • ID: 4894182
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 239 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Biocad
  • Clover Biopharmaceuticals
  • Hengenix Biotech Inc
  • Izana Bioscience Ltd
  • Nimbus Therapeutics LLC
  • MORE
Axial Spondyloarthritis - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Axial Spondyloarthritis - Pipeline Review, H2 2019, provides an overview of the Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline landscape.

Axial spondylitis is a type of inflammatory arthritis involving the spine and/or sacroiliac joints. Axial spondylitis is strongly related to the presence of the HLA-B27 gene. A genetic test for HLA-B27 is available.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Axial Spondyloarthritis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Axial Spondyloarthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Axial Spondyloarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 6, 1, 10, 2, 9, 1, 16 and 7 respectively.

Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Axial Spondyloarthritis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Axial Spondyloarthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Axial Spondyloarthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Axial Spondyloarthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Axial Spondyloarthritis (Musculoskeletal Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Axial Spondyloarthritis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Biocad
  • Clover Biopharmaceuticals
  • Hengenix Biotech Inc
  • Izana Bioscience Ltd
  • Nimbus Therapeutics LLC
  • MORE
Introduction
Axial Spondyloarthritis - Overview
Axial Spondyloarthritis - Therapeutics Development
Axial Spondyloarthritis - Therapeutics Assessment
Axial Spondyloarthritis - Companies Involved in Therapeutics Development
Axial Spondyloarthritis - Drug Profiles
Axial Spondyloarthritis - Dormant Projects
Axial Spondyloarthritis - Discontinued Products
Axial Spondyloarthritis - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Axial Spondyloarthritis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Axial Spondyloarthritis - Pipeline by AbbVie Inc, H2 2019
Axial Spondyloarthritis - Pipeline by Alvotech ehf, H2 2019
Axial Spondyloarthritis - Pipeline by Amgen Inc, H2 2019
Axial Spondyloarthritis - Pipeline by AstraZeneca Plc, H2 2019
Axial Spondyloarthritis - Pipeline by Beijing Eastern Biotech Co Ltd, H2 2019
Axial Spondyloarthritis - Pipeline by Bio-Thera Solutions Ltd, H2 2019
Axial Spondyloarthritis - Pipeline by Biocad, H2 2019
Axial Spondyloarthritis - Pipeline by Biocon Ltd, H2 2019
Axial Spondyloarthritis - Pipeline by BioXpress Therapeutics SA, H2 2019
Axial Spondyloarthritis - Pipeline by Clover Biopharmaceuticals, H2 2019
Axial Spondyloarthritis - Pipeline by DNX Biopharmaceuticals Inc, H2 2019
Axial Spondyloarthritis - Pipeline by Eli Lilly and Co, H2 2019
Axial Spondyloarthritis - Pipeline by FunPep Co Ltd, H2 2019
Axial Spondyloarthritis - Pipeline by Galapagos NV, H2 2019
Axial Spondyloarthritis - Pipeline by Hengenix Biotech Inc, H2 2019
Axial Spondyloarthritis - Pipeline by Huabo Biopharm Co Ltd, H2 2019
Axial Spondyloarthritis - Pipeline by Hualan Biological Engineering Inc, H2 2019
Axial Spondyloarthritis - Pipeline by Immunwork Inc, H2 2019
Axial Spondyloarthritis - Pipeline by Innovent Biologics Inc, H2 2019
Axial Spondyloarthritis - Pipeline by InSight Biopharmaceuticals Ltd, H2 2019
Axial Spondyloarthritis - Pipeline by Izana Bioscience Ltd, H2 2019
Axial Spondyloarthritis - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019
Axial Spondyloarthritis - Pipeline by JiangSu Qyuns Therapeutics Co Ltd, H2 2019
Axial Spondyloarthritis - Pipeline by Lupin Ltd, H2 2019
Axial Spondyloarthritis - Pipeline by Mycenax Biotech Inc, H2 2019
Axial Spondyloarthritis - Pipeline by NeuClone Pty Ltd, H2 2019
Axial Spondyloarthritis - Pipeline by Nichi-Iko Pharmaceutical Co Ltd, H2 2019
Axial Spondyloarthritis - Pipeline by Nimbus Therapeutics LLC, H2 2019
Axial Spondyloarthritis - Pipeline by Novartis AG, H2 2019
Axial Spondyloarthritis - Pipeline by Pfizer Inc, H2 2019
Axial Spondyloarthritis - Pipeline by Pharmapraxis, H2 2019
Axial Spondyloarthritis - Pipeline by RNAx Ltd, H2 2019
Axial Spondyloarthritis - Pipeline by Shandong Boan Biological Technology Co Ltd, H2 2019
Axial Spondyloarthritis - Pipeline by Shandong Danhong Pharmaceutical Co Ltd, H2 2019
Axial Spondyloarthritis - Pipeline by Shanghai Junshi Bioscience Co Ltd, H2 2019
Axial Spondyloarthritis - Pipeline by Siam Bioscience Co Ltd, H2 2019
Axial Spondyloarthritis - Pipeline by Sichuan Haisco Pharmaceutical Co Ltd, H2 2019
Axial Spondyloarthritis - Pipeline by Sino Biopharmaceutical Ltd, H2 2019
Axial Spondyloarthritis - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2019
Axial Spondyloarthritis - Pipeline by UCB SA, H2 2019
Axial Spondyloarthritis - Pipeline by Wuhan Institute of Biological Products Co Ltd, H2 2019
Axial Spondyloarthritis - Pipeline by Xbrane Biopharma AB, H2 2019
Axial Spondyloarthritis - Dormant Projects, H2 2019
Axial Spondyloarthritis - Dormant Projects, H2 2019 (Contd..1), H2 2019
Axial Spondyloarthritis - Dormant Projects, H2 2019 (Contd..2), H2 2019
Axial Spondyloarthritis - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Axial Spondyloarthritis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AbbVie Inc
  • Alvotech ehf
  • Amgen Inc
  • AstraZeneca Plc
  • Beijing Eastern Biotech Co Ltd
  • Bio-Thera Solutions Ltd
  • Biocad
  • Biocon Ltd
  • BioXpress Therapeutics SA
  • Clover Biopharmaceuticals
  • DNX Biopharmaceuticals Inc
  • Eli Lilly and Co
  • FunPep Co Ltd
  • Galapagos NV
  • Hengenix Biotech Inc
  • Huabo Biopharm Co Ltd
  • Hualan Biological Engineering Inc
  • Immunwork Inc
  • Innovent Biologics Inc
  • InSight Biopharmaceuticals Ltd
  • Izana Bioscience Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • JiangSu Qyuns Therapeutics Co Ltd
  • Lupin Ltd
  • Mycenax Biotech Inc
  • NeuClone Pty Ltd
  • Nichi-Iko Pharmaceutical Co Ltd
  • Nimbus Therapeutics LLC
  • Novartis AG
  • Pfizer Inc
  • Pharmapraxis
  • RNAx Ltd
  • Shandong Boan Biological Technology Co Ltd
  • Shandong Danhong Pharmaceutical Co Ltd
  • Shanghai Junshi Bioscience Co Ltd
  • Siam Bioscience Co Ltd
  • Sichuan Haisco Pharmaceutical Co Ltd
  • Sino Biopharmaceutical Ltd
  • Sun Pharma Advanced Research Company Ltd
  • UCB SA
  • Wuhan Institute of Biological Products Co Ltd
  • Xbrane Biopharma AB
Note: Product cover images may vary from those shown
Adroll
adroll